Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients

Nutrition Research

Volumn 32, Issue 7, 2012, Pages 495-502

  An, Won Suk ^a   Lee, Su Mi ^a   Son, Young Ki ^a   Kim, Seong Eun ^a   Kim, Ki Hyun ^a   Han, Jin Yeong ^a   Bae, Hae Rahn ^a   Rha, Seo Hee ^a   Park, Yongsoon ^b  

^a Dong A University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

1,25 dihydroxyvitamin D; Dialysis; Fetuin A; Fibroblast growth factor 23; Human; Omega 3 fatty acid

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; DOCOSAHEXAENOIC ACID; FETUIN A; FIBROBLAST GROWTH FACTOR 23; ICOSAPENTAENOIC ACID; LIPID; OLEIC ACID; OMEGA 3 ACID ETHYL ESTER; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGASTRIC PAIN; ERYTHROCYTE MEMBRANE; FEMALE; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; CALCIUM; CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; ENERGY INTAKE; ERYTHROCYTE MEMBRANE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MIDDLE AGED; OLEIC ACID; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHORUS; RADIOIMMUNOASSAY; RENAL DIALYSIS; VASCULAR CALCIFICATION; VITAMIN D;

EID: 84865195959     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.06.005     Document Type: Article

References (45)

1. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
2. Michos E.D., Melamed M.L. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008, 11:7-12.
3. Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
4. de Boer I.H., Kestenbaum B., Shoben A.B., Michos E.D., Sarnak M.J., Siscovick D.S. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009, 20:1805-1812.
5. Garcia-Canton C., Bosch E., Ramirez A., Gonzalez Y., Auyanet I., Guerra R., et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 2011, 26:2250-2256.
6. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
7. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
8. Tomiyama H., Takazawa K., Osa S., Hirose K., Hirai A., Iketani T., et al. Do eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia?: a preliminary study. Hypertens Res 2005, 28:651-655.
9. Hall W.L., Sanders K.A., Sanders T.A., Chowienczyk P.J. A high-fat meal enriched with eicosapentaenoic acid reduces postprandial arterial stiffness measured by digital volume pulse analysis in healthy men. J Nutr 2008, 138:287-291.
10. Kanai S., Uto K., Honda K., Hagiwara N., Oda H. Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats. Atherosclerosis 2011, 215:43-51.
11. Park Y., Kim M. Serum 25-hydroxyvitamin D concentrations are associated with erythrocyte levels of n-3 PUFA but not risk of CVD. Br J Nutr 2011, 1-6.
12. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366.
13. Hermans M.M., Brandenburg V., Ketteler M., Kooman J.P., van der Sande F.M., Gladziwa U., et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006, 21:1293-1299.
14. Jung J.Y., Hwang Y.H., Lee S.W., Lee H., Kim D.K., Kim S., et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010.
15. Wang A.Y., Woo J., Lam C.W., Wang M., Chan I.H., Gao P., et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005, 20:1676-1685.
16. Stenvinkel P., Wang K., Qureshi A.R., Axelsson J., Pecoits-Filho R., Gao P., et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005, 67:2383-2392.
17. Imel E.A., Econs M.J. Fibroblast growth factor 23: roles in health and disease. J Am SocNephrol 2005, 16:2565-2575.
18. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
19. Nasrallah M.M., El-Shehaby A.R., Salem M.M., Osman N.A., El Sheikh E., Sharaf El Din U.A. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:2679-2685.
20. Friedman A., Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am SocNephrol 2006, 1:182-192.
21. de Boer I.H., Kestenbaum B., Shoben A.B., Michos E.D., Sarnak M.J., Siscovick D.S. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am SocNephrol 2009, 20:1805-1812.
22. Svensson M., Schmidt E.B., Jorgensen K.A., Christensen J.H. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006, 1:780-786. OPACH Study Group.
23. Artaza J.N., Mehrotra R., Norris K.C. Vitamin D and the cardiovascular system. Clin J Am SocNephrol 2009, 4:1515-1522.
24. Zehnder D., Bland R., Walker E.A., Bradwell A.R., Howie A.J., Hewison M., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am SocNephrol 1999, 10:2465-2473.
25. Dusso A., Lopez-Hilker S., Rapp N., Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int 1988, 34:368-375.
26. Lambert P.W., Stern P.H., Avioli R.C., Brackett N.C., Turner R.T., Greene A., et al. Evidence for extrarenal production of 1 alpha,25-dihydroxyvitamin D in man. J Clin Invest 1982, 69:722-725.
27. Dusso A., Finch J., Delmez J., Rapp N., Lopez-Hilker S., Brown A., et al. Extrarenal production of calcitriol. Kidney Int Suppl 1990, 29:S36-S40.
28. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008, 110:c58-c65.
29. Helvig C.F., Cuerrier D., Hosfield C.M., Ireland B., Kharebov A.Z., Kim J.W., et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010, 78:463-472.
30. Ix J.H., Shlipak M.G., Brandenburg V.M., Ali S., Ketteler M., Whooley M.A. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006, 113:1760-1767.
31. Ix J.H., Wassel C.L., Chertow G.M., Koster A., Johnson K.C., Tylavsky F.A., et al. Fetuin-A and change in body composition in older persons. J Clin Endocrinol Metab 2009, 94:4492-4498.
32. Mori K., Emoto M., Yokoyama H., Araki T., Teramura M., Koyama H., et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 2006, 29:468.
33. Weikert C., Stefan N., Schulze M.B., Pischon T., Berger K., Joost H.G., et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008, 118:2555-2562.
34. Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Weissberg P.L., et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005, 16:2920-2930.
35. Szweras M., Liu D., Partridge E.A., Pawling J., Sukhu B., Clokie C., et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002, 277:19991-19997.
36. Leaf A., Kang J.X., Xiao Y.F., Billman G.E. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003, 107:2646-2652.
37. Siguel E.N., Lerman R.H. Altered fatty acid metabolism in patients with angiographically documented coronary artery disease. Metabolism 1994, 43:982-993.
38. Paganelli F., Maixent J.M., Duran M.J., Parhizgar R., Pieroni G., Sennoune S. Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. Int J Cardiol 2001, 78:27-32.
39. Block R.C., Harris W.S., Reid K.J., Spertus J.A. Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes?. Am Heart J 2008, 156:1117-1123.
40. An W.S., Lee S.M., Son Y.K., Kim S.E., Kim K.H., Han J.Y., et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot Essent Fatty Acids 2012, 86:29-34.
41. Katan M.B., Zock P.L., Mensink R.P. Dietary oils, serum lipoproteins, and coronary heart disease. Am J ClinNutr 1995, 61:1368S-1373S.
42. Grundy S.M. Dietary fat: at the heart of the matter. Science 2001, 293:801-804.
43. Trivedi H., Tan S.H., Prowant B., Sherman A., Voinescu C.G., Atalla J., et al. Predictors of death in patients on peritoneal dialysis: the Missouri Peritoneal Dialysis Study. Am J Nephrol 2005, 25:466-473.
44. Schmitz P.G., McCloud L.K., Reikes S.T., Leonard C.L., Gellens M.E. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002, 13:184-190.
45. Svensson M., Schmidt E.B., Jorgensen K.A., Christensen J.H. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol Dial Transplant 2008, 23:2918-2924.